About Dr. Cleeland
Charles Cleeland, MD Anderson's McCullough Professor of Cancer Research, is a leader in the area of cancer symptom epidemiology, assessment and treatment. He has directed epidemiological studies of pain and other symptoms in patients with cancer, studies of the mechanisms of pain and other symptoms, studies using PET and functional MRI to examine the effects of pain on cortical activity, and clinical trials aimed at reducing the risk of inadequate symptom control, including in underserved populations.
Dr. Cleeland is senior scientific advisor of the Pan American Health Organization/WHO. He is a member and past president of the board of directors of the United States Cancer Pain Relief Committee. He is also past president of the American Pain Society.
Dr. Cleeland's research is widely published. He has published numerous studies of the prevalence and severity of cancer pain, of U.S. and international symptom management practice patterns, and of potential biological mechanisms underlying the symptoms produced by cancer and its treatment.
Clinical Research Director, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
McCullough Professor of Cancer Research, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dr. Cleeland and his colleagues in the Department of Symptom Research have developed assessment tools (the Brief Pain Inventory, Brief Fatigue Inventory, and M. D. Anderson Symptom Inventory) to measure symptom severity and how symptoms interfere with patient functioning. These tools are widely used internationally in clinical trials evaluating symptom-management treatments.
As Director of the WHO Collaborating Center for Supportive Cancer Care, Dr. Cleeland worked with colleagues in Asia, Europe, and the United States to verify that our symptom-assessment scales work well in various linguistic and cultural contexts to allow development of multinational clinical trials and cross-cultural epidemiological symptom studies. Through ongoing international collaborations, he works to further the stateside training of clinicians and researchers from other countries, provide resources to educate abroad, encourage treatment of cancer-related pain and other symptoms for those without access to expensive curative treatments, and promote palliative care programs in countries with limited health care resources.
Dr. Cleeland's long-term research goals are to prevent the development of symptoms and to develop enhanced treatments for the symptoms of cancer and cancer treatment, which may lead to improvement in patient function, stress level, satisfaction with and willingness to endure therapy, and quality of life during and after treatment. He is especially interested in the role of inflammation as a physiological mechanism potentially responsible for symptom-cluster generation and in biological response modifiers as agents for symptom reduction and prevention. Based on animal models of inflammation-induced sickness behavior, he hypothesizes that inflammation and its downstream toxic effects represent a significant biological basis for subjectively reported clusters of symptoms, cognitive impairment, and neuropathies. Control or prevention of cancer-related cytokine dysregulation may provide a basis for experimental therapies that could significantly reduce or even preclude the emergence of cancer-related symptoms.
|1966||Washington University, St. Louis, MO, USA, PHD, Clinical Psychology|
|1960||Wesleyan University, Middletown, CT, USA, BA, Psychology|
|1965-1967||NIH Postdoctoral Fellow, Neurology, University of Wisconsin, Madison, WI|
|1982||Fellow, American Psychological Association (Clinical)|
|1978||Diplomate in Clinical Psychology, American Board of Professional Psychology|
|2017||Robert F. Gagel Lifetime Achievement Award, UT MD Anderson Division of Internal Medicine|
|2010||Raymond Houde Award and Lecture, Eastern Pain Society|
|2009||Award for Excellence in Contributions to the Committee for Rehabilitation and Palliative Care, The Chinese Anti-Cancer Association|
|2008||30th Annual Dr. John J. Bonica Award, Eastern Pain Association|
|2007||Trish Greene Quality of Life Award, American Cancer Society|
|2002||Fordyce Clinical Investigator Award, American Pain Society|
|2000||Distinguished Service Award, American Pain Society|
- Shi Q, Mendoza TR, Dueck AC, Ma H, Zhang J, Qian Y, Bhowmik D, Cleeland CS. Determination of mild, moderate, and severe pain interference in patients with cancer. Pain 158(6):1108-1112, 2017. PMID: 28267060.
- Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017. e-Pub 2017. PMID: 28089238.
- Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro J, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJ, Velikova G, Coens C, Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol 17(11):e510-e514, 2016. e-Pub 2016. PMID: 27769798.
- Shi Q, Mendoza TR, Wang XS, Cleeland CS. Using a symptom-specific instrument to measure patient-reported daily functioning in patients with cancer. Eur J Cancer 67:83-90, 2016. e-Pub 2016. PMID: 27620946.
- Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E, National Cancer Institute PRO-CTCAE Study Group. Validity and reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 1(8):1051-9, 2015. e-Pub 2015. PMID: 26270597.
- Williams LA, Agarwal S, Bodurka DC, Saleeba AK, Sun CC, Cleeland CS. Capturing the patient's experience: using qualitative methods to develop a measure of patient-reported symptom burden: an example from ovarian cancer. J Pain Symptom Manage 46(6):837-45, 2013. e-Pub 2013. PMID: 23615044.
- Jones D, Vichaya EG, Wang XS, Sailors MH, Cleeland CS, Wefel JS. Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Cancer 119(23):4188-95, 2013. e-Pub 2013. PMID: 24105672.
- Cleeland CS, Zhao F, Chang VT, Sloan JA, O'Mara AM, Gilman PB, Weiss M, Mendoza TR, Lee JW, Fisch MJ. The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer 119(24):4333-40, 2013. e-Pub 2013. PMID: 24114037.
- Shi Q, Mendoza TR, Gunn GB, Wang XS, Rosenthal DI, Cleeland CS. Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. Qual Life Res 22(9):2331-9, 2013. e-Pub 2013. PMID: 23475689.
- Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol 14(12):1193-9, 2013. e-Pub 2013. PMID: 24075621.
- Gunn GB, Mendoza TR, Fuller CD, Gning I, Frank SJ, Beadle BM, Hanna EY, Lu C, Cleeland CS, Rosenthal DI. High symptom burden prior to radiation therapy for head and neck cancer: A patient-reported outcomes study. Head Neck 35(10):1490-8, 2013. e-Pub 2012. PMID: 23169304.
- Williams LA, Garcia Gonzalez AG, Ault P, Mendoza TR, Sailors ML, Williams JL, Huang F, Nazha A, Kantarjian HM, Cleeland CS, Cortes JE. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 122(5):641-7, 2013. e-Pub 2013. PMID: 23777764.
- Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, Chung K. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 119(4):832-8, 2013. e-Pub 2012. PMID: 22951813.
- Cleeland CS, Sloan JA, Cella D, Chen C, Dueck AC, Janjan NA, Liepa AM, Mallick R, O'Mara A, Pearson JD, Torigoe Y, Wang XS, Williams LA, Woodruff JF, CPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force. Recommendations for including multiple symptoms as endpoints in cancer clinical trials : A report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force. Cancer 119(2):411-20, 2013. e-Pub 2012. PMID: 22930243.
- Cleeland CS, Allen JD, Roberts SA, Brell JM, Giralt SA, Khakoo AY, Kirch RA, Kwitkowski VE, Liao Z, Skillings J. Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nat Rev Clin Oncol 9(8):471-8, 2012. e-Pub 2012. PMID: 22751283.
- Wang XS, Williams LA, Krishnan S, Liao Z, Liu P, Mao L, Shi Q, Mobley GM, Woodruff JF, Cleeland CS. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun 26(5):699-705, 2012. e-Pub 2012. PMID: 22251605.
- Dantzer R, Meagher MW, Cleeland CS. Translational approaches to treatment-induced symptoms in cancer patients. Nat Rev Clin Oncol 9(7):414-26, 2012. e-Pub 2012. PMID: 22641361.
- Boyette-Davis JA, Eng C, Wang XS, Cleeland CS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Zhang H, Dougherty PM. Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. Clin Cancer Res 18(11):3180-7, 2012. e-Pub 2012. PMID: 22496202.
- Fisch MJ, Lee JW, Weiss M, Wagner LI, Chang VT, Cella D, Manola JB, Minasian LM, McCaskill-Stevens W, Mendoza TR, Cleeland CS. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 30(16):1980-8, 2012. e-Pub 2012. PMID: 22508819.
- Mendoza TR, Koyyalagunta D, Burton AW, Thomas SK, Phan MH, Giralt SA, Shah JJ, Cleeland CS. Changes in pain and other symptoms in patients with painful multiple myeloma-related vertebral fracture treated with kyphoplasty or vertebroplasty. J Pain 13(6):564-70, 2012. e-Pub 2012. PMID: 22543044.
- Wang XS, Rhines LD, Shiu AS, Yang JN, Selek U, Gning I, Liu P, Allen PK, Azeem SS, Brown PD, Sharp HJ, Weksberg DC, Cleeland CS, Chang EL. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol 13(4):395-402, 2012. e-Pub 2012. PMID: 22285199.
- Quinten C, Maringwa J, Gotay CC, Martinelli F, Coens C, Reeve BB, Flechtner H, Greimel E, King M, Osoba D, Cleeland C, Ringash J, Schmucker-Von Koch J, Taphoorn MJ, Weis J, Bottomley A. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst 103(24):1851-8, 2011. e-Pub 2011. PMID: 22157640.
- Cleeland CS, O'Mara A, Zagari M, Baas C. Integrating pain metrics into oncology clinical trials. Clin Cancer Res 17(21):6646-50, 2011. PMID: 22046026.
- Cleeland CS, Mendoza TR, Wang XS, Woodruff JF, Palos GR, Richman SP, Nazario A, Lynch GR, Liao KP, Mobley GM, Lu C. Levels of symptom burden during chemotherapy for advanced lung cancer: differences between public hospitals and a tertiary cancer center. J Clin Oncol 29(21):2859-65, 2011. e-Pub 2011. PMID: 21690477.
- Cleeland CS, Wang XS, Shi Q, Mendoza TR, Wright SL, Berry MD, Malveaux D, Shah PK, Gning I, Hofstetter WL, Putnam JB, Vaporciyan AA. Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial. J Clin Oncol 29(8):994-1000, 2011. e-Pub 2011. PMID: 21282546.
- Mendoza TR, Wang XS, Lu C, Palos GR, Liao Z, Mobley GM, Kapoor S, Cleeland CS. Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. Oncologist 16(2):217-27, 2011. e-Pub 2011. PMID: 21285393.
- Wang XS, Shi Q, Williams LA, Mao L, Cleeland CS, Komaki RR, Mobley GM, Liao Z. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 24(6):968-74, 2010. e-Pub 2010. PMID: 20353817.
- Barsevick AM, Cleeland CS, Manning DC, O'Mara AM, Reeve BB, Scott JA, Sloan JA, ASCPRO (Assessing Symptoms of Cancer Using Patient-Reported Outcomes). ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials. J Pain Symptom Manage 39(6):1086-99, 2010. PMID: 20538190.
- Wang XS, Cleeland CS, Mendoza TR, Yun YH, Wang Y, Okuyama T, Johnson VE. Impact of cultural and linguistic factors on symptom reporting by patients with cancer. J Natl Cancer Inst 102(10):732-738, 2010. e-Pub 2010. PMID: 20348233.
- Wang XS, Williams LA, Eng C, Mendoza TR, Shah NA, Kirkendoll KJ, Shah PK, Trask PC, Palos GR, Cleeland CS. Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer 116(8):2053-63, 2010. e-Pub 2010. PMID: 20166216.
- Atkinson TM, Mendoza TR, Sit L, Passik S, Scher HI, Cleeland C, Basch E. The Brief Pain Inventory and its "Pain at its worst in the last 24 hours" item: clinical trial endpoint considerations. Pain Med 11(3):337-46, 2010. e-Pub 2010. PMID: 20030743.
- Wang XS, Shi Q, Lu C, Basch EM, Johnson VE, Mendoza TR, Mobley GM, Cleeland CS. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced non-small cell lung cancer. Cancer 116(1):137-45, 2010. e-Pub 2009. PMID: 19852033.
- Shi Q, Wang XS, Mendoza TR, Pandya KJ, Cleeland CS. Assessing persistent cancer pain: a comparison of current-pain ratings and pain recalled from the past week. J Pain Symptom Manage 37(2):168-74, 2009. e-Pub 2008. PMID: 18676116.
- Rosenthal DI, Mendoza TR, Chambers MS, Burkett VS, Garden AS, Hessell AC, Lewin JS, Ang KK, Kies MS, Gning I, Wang XS, Cleeland CS. The M. D. Anderson Symptom Inventory-Head and Neck Module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis. Int J Radiat Oncol Biol Phys 72(5):1355-61, 2008. e-Pub 2008. PMID: 18501527.
- Wang XS, Shi Q, Williams LA, Cleeland CS, Mobley GM, Reuben JM, Lee BN, Giralt SA. Serum IL-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer 113(8):2102-9, 2008. e-Pub 2008. PMID: 18792065.
- Wang XS, Fairclough DL, Liao Z, Komaki R, Chang JY, Mobley GM, Cleeland CS. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol 24(27):4485-91, 2006. PMID: 16983118.
- Cleeland CS, Portenoy RK, Rue M, Mendoza TR, Weller E, Payne R, Kirshner J, Atkins JN, Johnson PA, Marcus A. Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group. Ann Oncol 16(6):972-80, 2005. PMID: 15821119.
- Lee BN, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, Dunn AJ, Meyers CA, Miller AH, Payne R, Reuben JM, Wang XS, Cleeland CS. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 11(5):279-92, 2004. PMID: 15316238.
- Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC. Assessing symptom distress in cancer patients: the M. D. Anderson Symptom Inventory. Cancer 89(7):1634-46, 2000. PMID: 11013380.
- Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61(2):277-84, 1995. PMID: 7659438.
- Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330(9):592-6, 1994. PMID: 7508092.
- Cleeland CS. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monographs 37:16-21, 2007.
- Wang XS, Cleeland CS.. Symptoms that cluster around cancer pain: a research agenda. Pain: Clinical Updates XIV(5):1-4, 2006.
- Cleeland CS, Mendoza TR. Symptom measurement by patient report. In: Cancer Symptom Science: Measurement, Mechanisms, and Management. Cambridge University Press: Cambridge UK, 268-84, 2011.
- Cleeland CS, Fisch MJ, Dunn AJ.. Symptom research: looking ahead. In: Cancer Symptom Science: Measurement, Mechanisms, and Management. Cambridge University Press: Cambridge UK, 341-8, 2011.
- Shi Q, Cleeland CS. Genetic approaches to treating and preventing symptoms in patients with cancer. In: Cancer Symptom Science: Measurement, Mechanisms, and Management. Cambridge University Press: Cambridge UK, 192-205, 2011.
Books (edited and written)
- Cleeland CS, Fisch MJ, Dunn AJ. Cancer Symptom Science: Measurement, Mechanisms, and Management. Ed(s) Cleeland CS, Fisch MJ, Dunn AJ. Cambridge University Press: Cambridge, UK, 2011.
|Title:||Assessing PROMIS and Other Simple Patient Reported Measures for Cancer Research|
|Funding Source:||Mayo Clinic|
|Title:||Development of a Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)|
|Funding Source:||Memorial Sloan Kettering Cancer Center|
|Title:||The Effect of Recall Period on Patients Ratings of Severity of Multiple Symptoms|
|Title:||Reducing the Symptom Burden Produced by Aggressive Cancer Therapies|